Tumor Genomic Profiling denied for missing prior authorization by Avalon Healthcare Solutions?

Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.

Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.

## Why Avalon Healthcare Solutions Requires Prior Authorization for Tumor Genomic Profiling — and How to Appeal a Denial

Avalon Healthcare Solutions administers specialty genomic and laboratory benefit management for many health plans and requires prior authorization (PA) for tumor genomic profiling (CGP) as part of its clinical gatekeeping function. The PA process is meant to confirm that the test is ordered for an appropriate cancer type and clinical situation, that the ordering provider has documented a clear rationale for how results will affect treatment decisions, and that the test aligns with Avalon's coverage criteria. A PA denial means one or more of those criteria were not sufficiently documented — not necessarily that the test is inappropriate.

## Why Prior-Auth Denials for CGP Are Routinely Overturned

The most common reason for CGP PA denials is insufficient clinical documentation in the initial request — especially the absence of a clear explanation of how test results would change management. When the treating oncologist provides a detailed, criteria-specific letter, the denial is often reversed at the first level of internal appeal, before external review is even needed.

## Federal Appeal Framework

Under ACA Section 2719, prior authorization denials are full coverage denials subject to internal appeal and independent external review. ERISA Section 503 applies to employer-sponsored plans. External review must generally be requested within approximately four months of the final internal denial. For oncology cases where treatment decisions are time-sensitive, expedited internal and external review are available — request these explicitly and document the clinical urgency.

## What to Gather Before You Appeal

• Avalon's prior authorization criteria for tumor genomic profiling. Download the current published policy from Avalon's website before drafting the appeal. Map every criterion to your clinical records. Do not assume you know what criteria apply — Avalon's policies are detailed and version-specific.
• PA denial letter. Confirm exactly which criteria Avalon found unmet and whether there were any documentation gaps in the original submission.
• Treating oncologist's medical-necessity letter. This is the most important document. The letter should address each PA criterion specifically: (a) cancer type, histology, and stage; (b) current line of therapy and prior treatment history with dates and outcomes; (c) why CGP is clinically necessary for this patient at this time; (d) which clinical questions the test would answer; and (e) how results would directly guide treatment selection. Reference the applicable NCCN guideline generically.
• Pathology report and staging workup. Provide the formal pathology report confirming tumor type and any biomarkers already known. These documents establish the clinical baseline Avalon's criteria build on.
• Prior molecular testing results. If earlier tests were done, document them — this shows the clinical reasoning for why more comprehensive testing is now needed.

## Criteria-Mapping Structure

| Avalon PA criterion (from published policy) | Chart evidence | Document | |---|---|---| | Cancer type within covered indications | Pathology report + diagnosis code | Pathology report, date | | Stage / disease status | Staging workup | Imaging + chart notes | | Prior therapy (if required) | Treatment log with dates and outcomes | Oncologist letter + records | | Results will change management | Specific treatment-decision rationale | Oncologist letter | | Ordering provider credentials | Specialty confirmation | If requested |

## Practical Advice

Include every document in the first appeal submission — incomplete appeals invite a second denial on different grounds. If Avalon allows a peer-to-peer review between their medical director and the treating oncologist, schedule it immediately in parallel with the written appeal. Peer-to-peer reviews resolve many PA denials before the formal appeal process concludes.